The newest drugs emerging in the market for gene and cell therapy as well as disposables have become the focus area for U.S. bioprocessing firms, many of whom have been moving some production overseas—particularly to Europe. But while single-use products have advantages in production costs and turnaround time, there remain challenges for American biopharma companies…